# Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients

> **NCT03664843** · — · UNKNOWN · sponsor: **First Hospital of Shijiazhuang City** · enrollment: 120 (estimated)

## Conditions studied

- Carcinoma
- Non-small Cell Lung Cancer
- Lung Neoplasm

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03664843
- **Lead sponsor:** First Hospital of Shijiazhuang City
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-09
- **Primary completion:** 2020-05-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2018-11-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03664843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03664843, "Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03664843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*